Gene Therapy for Parkinson's Disease Using Midbrain Developmental Genes to Regulate Dopaminergic Neuronal Maintenance

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Parkinson's disease (PD) is a prevalent neurodegenerative disorder marked by dopamine neuron loss and reduced dopamine levels.
• Current treatments manage symptoms but do not halt PD progression.
• Gene therapy presents a promising alternative with potential for symptom relief and fewer side effects.

Purpose of the Study:

• To review current gene therapy strategies for Parkinson's disease.
• To explore novel therapeutic approaches targeting disease modification and neuroprotection.

Main Methods:

• Review of preclinical and clinical trial data on gene therapies for PD.
• Analysis of studies investigating neurotrophic factors, developmental factors (Nurr1, Foxa2), and downstream pathway modulation.
• Examination of advancements in gene editing and delivery techniques.

Main Results:

• Adeno-associated virus (AAV)-mediated gene therapies (e.g., GAD, AADC) show safety and efficacy in early trials for dopamine replacement.
• Disease-modifying strategies targeting neuronal integrity (e.g., Nurr1, Foxa2) and neurotrophic factors (GDNF, BDNF, VEGF) demonstrate potential.
• Targeting pathways like autophagy, mitochondrial function, and ER stress shows promise for neuroprotection.

Conclusions:

• Gene therapy offers significant potential for both symptomatic relief and disease modification in Parkinson's disease.
• Future research should focus on synergistic approaches targeting neurons and glia, alongside advanced gene editing techniques for effective PD treatment.